Innate Pharma SA (FR:IPH) has released an update.
Innate Pharma SA, in collaboration with Sanofi, has shared promising updated results from its Phase 1/2 trial of SAR443579/IPH6101, an investigational therapy for blood cancers, at the European Hematology Association Congress. The therapy, targeting CD123 and leveraging the ANKET® platform, demonstrated clinical benefits and safety, with five patients achieving complete remission and three showing durable responses. These results have propelled the study into Phase 2, marking a significant advancement in its development.
For further insights into FR:IPH stock, check out TipRanks’ Stock Analysis page.
